In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...
"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...
A HEALTHCARE worker has told show she almost died after fat loss jabs she ordered from Facebook were feared to have been ...
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...
Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...
Doctors say they have not seen anything like this since the emergence of statins to lower cholesterol. But do we know enough ...
Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...
In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback